Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
1996-12-9
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0195-668X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
17
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
648-50
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:8737090-Angiotensin-Converting Enzyme Inhibitors,
pubmed-meshheading:8737090-Captopril,
pubmed-meshheading:8737090-Cardiac Output, Low,
pubmed-meshheading:8737090-Cost-Benefit Analysis,
pubmed-meshheading:8737090-Drug Costs,
pubmed-meshheading:8737090-Humans,
pubmed-meshheading:8737090-Myocardial Infarction,
pubmed-meshheading:8737090-Preventive Medicine
|
pubmed:year |
1996
|
pubmed:articleTitle |
Economic aspects of treatment with captopril after MI.
|
pubmed:publicationType |
Editorial,
Comment
|